NCT05246670View on ClinicalTrials.gov

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

February 12, 2024

Study Completion Date

February 28, 2026

Conditions
Chemotherapy-Induced Peripheral NeuropathyHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Interventions
DRUG

Palmidrol

Given PEA PO

DRUG

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (10)

17822

Geisinger Medical Center, Danville

27403

Cone Health Cancer Center, Greensboro

37232

Vanderbilt University/Ingram Cancer Center, Nashville

51101

Siouxland Regional Cancer Center, Sioux City

54601

Mayo Clinic Health System-Franciscan Healthcare, La Crosse

54703

Mayo Clinic Health System Eau Claire Hospital-Luther Campus, Eau Claire

55905

Mayo Clinic, Rochester

57701

Rapid City Regional Hospital, Rapid City

61801

Carle Cancer Center NCI Community Oncology Research Program, Urbana

06457

Middlesex Hospital, Middletown

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER